This is the third competing continuation application for the Cancer Center Support Grant at Vanderbilt lngram Cancer Center (VICC). VICC is a matrix center within Vanderbilt University Medical Center (VUMC) that integrates the cancer-related expertise and resources of the Schools of Medicine, Nursing, Arts and Sciences, Engineering;Peabody School of Education and the fully integrated Veterans Administration Medical Center. Most facilities are located on one campus, which promotes interactions, sharing of resources, and collaborations. Established in 1993, VICC functions as an organizational unit with a supra-departmental status. VICC-specific authorities and responsibilities are: 1) to conduct, coordinate and integrate cancer-related activities of Vanderbilt University;2) to carry out, support and enhance cancer research throughout the University;3) to develop, manage, and provide cancer education programs;and 4) to coordinate and integrate the care of cancer patients at VUMC. The research objectives are accomplished through seven research programs, two of which evolved out of previous programs and are considered new since the previous application. The programs are: Host-Tumor Interactions, Signal Transduction and Cell Proliferation, Genome Maintenance (new), Gastrointestinal Cancer, Thoracic/Head &Neck Cancer (new), Breast Cancer, and Cancer Epidemiology, Prevention and Control. Thirteen shared resources are proposed, 11 previously supported and two new. There has been remarkable VICC growth and accomplishments over the past project period. VICC has been awarded 11 new multi-investigator and six new training grants. In addition, we successfully renewed all three NCI SPOREs as well as eight multi-investigator and 11 training grants. With these and many other NCI grants, we increased our NCI funding by 62%. Significant investments have been made in cancer drug discovery, personalized cancer medicine, cancer epidemiology prevention and control, genomics, proteomics, informatics, bioinformatics, diversity initiatives, and cancer health disparities. Increased VICC space and facilities, along with philanthropic and institutional funds, supported the recruitment of 66 new faculty, who join a dedicated team carrying out the VICC mission: to alleviate cancer death and suffering through pioneering research, innovative clinical trials, evidence-based patient-care, prevention, education, and community activities.

Public Health Relevance

The Vanderbilt-lngram Cancer Center Support Grant provides the infrastructure support to facilitate basic, clinical and population-based research relevant to our mission to alleviate cancer death and suffering through pioneering research, innovative patient care, evidence-based prevention, education and communication. Our vision is to be a preeminent cancer center in the Southeast and a recognized leader, nationally and globally in the effort to prevent and treat cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-17
Application #
8544989
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-17
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
17
Fiscal Year
2013
Total Cost
$5,600,513
Indirect Cost
$2,010,499
Name
Vanderbilt University Medical Center
Department
Biochemistry
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Bolus, W Reid; Peterson, Kristin R; Hubler, Merla J et al. (2018) Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab 8:86-95
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581
Wu, Jie; Cai, Hui; Xiang, Yong-Bing et al. (2018) Intra-individual variation of miRNA expression levels in human plasma samples. Biomarkers 23:339-346
Cardin, Dana B; Goff, Laura W; Chan, Emily et al. (2018) Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 36:442-450
Yang, Jinming; Kumar, Amrendra; Vilgelm, Anna E et al. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res 6:1186-1198
Alvarado, Gabriela; Ettayebi, Khalil; Atmar, Robert L et al. (2018) Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. Gastroenterology 155:1898-1907
Sierra, Johanna C; Asim, Mohammad; Verriere, Thomas G et al. (2018) Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut 67:1247-1260

Showing the most recent 10 out of 2462 publications